P/B
9,5
Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
$15.5B
Market Cap • 9/18/2026
2006
(20 years)
Founded
2015
(11 years ago)
IPO
NASDAQ
Listing Exchange
Denmark
Country
Valuation
P/S
12,8
P/EBITDA
46,3
P/OCF
38,7
P/FCF
38,7
P/E
18,6
BVPS
25,7
EPS
12,7
Market Cap
Market Cap
15,5B
EV
15,1B
EV/Revenue
12,5
EV/EBITDA
45,1
EV/EBIT
49,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,1%
Total Yield
-0,1%
Payout
0%
Retained Earnings
1,6B
Profitability
Gross Margin
91,3%
EBITDA Margin
27,7%
EBIT Margin
25,1%
Net Margin
70,3%
D&A/EBITDA
0%
R&D/Revenue
26,8%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
34,7%
% PPE
5,9%
% Goodwill
0%
ROE
120,4%
ROIC
249,3%
Growth
CAGR Revenue 5Y
186,7%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
3
Quick Ratio
2,2
Interest Coverage
124,3%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!